Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
132.16
-0.27 (-0.20%)
At close: Dec 5, 2025, 4:00 PM EST
132.22
+0.06 (0.05%)
After-hours: Dec 5, 2025, 7:08 PM EST
Novartis AG Revenue
Novartis AG had revenue of $14.36B in the quarter ending September 30, 2025, with 9.00% growth. This brings the company's revenue in the last twelve months to $56.37B, up 12.88% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$56.37B
Revenue Growth
+12.88%
P/S Ratio
4.53
Revenue / Employee
$742,880
Employees
75,883
Market Cap
255.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
NVS News
- 4 days ago - Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript - Seeking Alpha
- 10 days ago - Why Novartis Stock Topped the Market Today - The Motley Fool
- 10 days ago - FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults - Benzinga
- 10 days ago - Novartis plans to cut up to 550 jobs at Swiss facility - Reuters
- 10 days ago - Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS - GlobeNewsWire
- 11 days ago - Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community - GlobeNewsWire
- 11 days ago - FDA approves Novartis' gene therapy for rare muscle disorder - Reuters
- 11 days ago - Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA) - GlobeNewsWire